Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Core Insights - Tenaya Therapeutics is set to present new clinical and disease burden data related to its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific Session from March 29-31, 2025 [1][2] Group 1: Clinical Developments - The company is advancing TN-201, an AAV9-based gene therapy targeting MYBPC3-associated HCM, which is caused by insufficient levels of myosin-binding protein C (MyBP-C) [2][5] - Data from the MyPEAK-1 Phase 1b/2 clinical trial will be presented, including one-year assessments of the first two patients and six-month assessments from a third patient in the 3E13 vg/kg cohort [2][3] Group 2: Research Findings - A poster presentation will discuss findings from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), highlighting differences in disease burden among adults with HCM due to MYBPC3 mutations [3][6] - The presentations will be made by notable experts, including Dr. Milind Desai from the Cleveland Clinic [2][6] Group 3: Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease, with a pipeline that includes TN-201, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction [5]